1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Oct 2025
Admin
News Article

FRC's Tony Perkins Comments on the FDA's Dangerous Approval of Generic Abortion Drug

Family Research Council President Tony Perkins released the following statement reacting to the Food and Drug Administration's approval of a generic form of the abortion drug mifepristone hours ahead of the government shutdown:

""Despite the mounting evidence of the dangers of the abortion kill pills, the FDA approved a generic version of mifepristone just hours before the federal government shutdown. Under Biden-era policies, abortionists are operating like Amazon, shipping the life-ending drugs to anyone who clicks send. The Trump administration must change the Biden-era policy that is undermining the pro-life laws that dozens of states have enacted since Dobbs recognized their right to do so. The federal government is undermining states and the intent of the Dobbs decision,"" Perkins concluded.

Mary Szoch, FRC's Director of Center for Human Dignity, also commented:

The approval of another generic form of mifepristone should never have been granted. The latest data shows 11 percent of women have a serious complication following the use of this drug, and so a review of the drug is taking place. The FDA's expansion of the availability of mifepristone demonstrates the immediate need for the results of an unbiased, transparent review. As the FDA waits for that review to take place, we call on them to courageously reinstate the original safety measures for mifepristone strengthened with a requirement for an ultrasound. This will at least mitigate the danger to women and the unborn as we wait for this dangerous drug's approval to ideally be revoked.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!